{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T05:40:46Z","timestamp":1737870046802,"version":"3.33.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,25]]},"DOI":"10.7759\/cureus.77964","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T14:30:05Z","timestamp":1737815405000},"source":"Crossref","is-referenced-by-count":0,"title":["Timing and Patterns of Potentially Salvageable Recurrences Following Stereotactic Body Radiosurgery for Clinically Localized Prostate Cancer Assessed by Preferential Amino Acid Uptake"],"prefix":"10.7759","author":[{"given":"Tim","family":"Kearney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Carrasquilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan AU","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, et al.. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019, 2:e188006. 10.1001\/jamanetworkopen.2018.8006","journal-title":"JAMA Netw Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240939","article-title":"Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes","volume":"13","author":"Carrasquilla M","year":"2023","unstructured":"Carrasquilla M, Sholklapper T, Pepin AN, et al.. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes. Front Oncol. 2023, 13:1240939. 10.3389\/fonc.2023.1240939","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams R","year":"2021","unstructured":"van Dams R, Jiang NY, Fuller DB, et al.. Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients. Int J Radiat Oncol Biol Phys. 2021, 110:731-7. 10.1016\/j.ijrobp.2021.01.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt DE","year":"2013","unstructured":"Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013, 85:686-92. 10.1016\/j.ijrobp.2012.05.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.551491","article-title":"Management of isolated local failures following stereotactic body radiation therapy for low to intermediate risk prostate cancer","volume":"10","author":"Aghdam N","year":"2020","unstructured":"Aghdam N, Pepin AN, Creswell M, et al.. Management of isolated local failures following stereotactic body radiation therapy for low to intermediate risk prostate cancer. Front Oncol. 2020, 10:551491. 10.3389\/fonc.2020.551491","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound CR","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999, 281:1591-7. 10.1001\/jama.281.17.1591","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach M","year":"2006","unstructured":"Roach M, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006, 65:965-74. 10.1016\/j.ijrobp.2006.04.029","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.11.005","article-title":"Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: the Phoenix definition and beyond","volume":"166","author":"Ma TM","year":"2022","unstructured":"Ma TM, Roy S, Wu X, et al.. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: the Phoenix definition and beyond. Radiother Oncol. 2022, 166:1-7. 10.1016\/j.radonc.2021.11.005","journal-title":"Radiother Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma TM","year":"2022","unstructured":"Ma TM, Chu FI, Sandler H, et al.. Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN). Eur Urol. 2022, 82:487-98. 10.1016\/j.eururo.2022.07.011","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28446","article-title":"Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry","volume":"120","author":"Cary KC","year":"2014","unstructured":"Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer. 2014, 120:507-12. 10.1002\/cncr.28446","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13797","article-title":"State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer","volume":"26","author":"Schiavina R","year":"2019","unstructured":"Schiavina R, Chessa F, Borghesi M, et al.. State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. Int J Urol. 2019, 26:18-30. 10.1111\/iju.13797","journal-title":"Int J Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.017","article-title":"Prostate-specific membrane antigen and fluciclovine transporter genes are associated with variable clinical features and molecular subtypes of primary prostate cancer","volume":"79","author":"Chu CE","year":"2021","unstructured":"Chu CE, Alshalalfa M, Sj\u00f6str\u00f6m M, et al.. Prostate-specific membrane antigen and fluciclovine transporter genes are associated with variable clinical features and molecular subtypes of primary prostate cancer. Eur Urol. 2021, 79:717-21. 10.1016\/j.eururo.2021.03.017","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2021.05.008","article-title":"PET imaging for prostate cancer","volume":"59","author":"Savir-Baruch B","year":"2021","unstructured":"Savir-Baruch B, Werner RA, Rowe SP, Schuster DM. PET imaging for prostate cancer. Radiol Clin North Am. 2021, 59:801-11. 10.1016\/j.rcl.2021.05.008","journal-title":"Radiol Clin North Am"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.119.227116","article-title":"Best practices for (18)F-fluciclovine PET\/CT imaging of recurrent prostate cancer: a guide for technologists","volume":"47","author":"Tade FI","year":"2019","unstructured":"Tade FI, Sajdak RA, Gabriel M, Wagner RH, Savir-Baruch B. Best practices for (18)F-fluciclovine PET\/CT imaging of recurrent prostate cancer: a guide for technologists. J Nucl Med Technol. 2019, 47:282-7. 10.2967\/jnmt.119.227116","journal-title":"J Nucl Med Technol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.09.018","article-title":"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine ((18)F) PET\/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer","volume":"108","author":"Jani A","year":"2020","unstructured":"Jani A, Schreibmann E, Goyal S, et al.. Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine ((18)F) PET\/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2020, 108:1397. 10.1016\/j.ijrobp.2020.09.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.01.050","article-title":"Effect of (18)F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial","volume":"107","author":"Scarsbrook AF","year":"2020","unstructured":"Scarsbrook AF, Bottomley D, Teoh EJ, et al.. Effect of (18)F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial. Int J Radiat Oncol Biol Phys. 2020, 107:316-24. 10.1016\/j.ijrobp.2020.01.050","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0163-0","article-title":"The use of (68)Ga-PET\/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy","volume":"22","author":"Raveenthiran S","year":"2019","unstructured":"Raveenthiran S, Yaxley J, Gianduzzo T, et al.. The use of (68)Ga-PET\/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer Prostatic Dis. 2019, 22:385-90. 10.1038\/s41391-019-0163-0","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.02.014","article-title":"Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: implications for potential salvage","volume":"169","author":"Maitre P","year":"2022","unstructured":"Maitre P, Sood S, Pathare P, Krishnatry R, Agrawal A, Rangarajan V, Murthy V. Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: implications for potential salvage. Radiother Oncol. 2022, 169:71-6. 10.1016\/j.radonc.2022.02.014","journal-title":"Radiother Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen LN","year":"2013","unstructured":"Chen LN, Suy S, Uhm S, et al.. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013, 8:58. 10.1186\/1748-717X-8-58","journal-title":"Radiat Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00114","article-title":"Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: the Georgetown University experience","volume":"6","author":"Mercado C","year":"2016","unstructured":"Mercado C, Kress MA, Cyr RA, et al.. Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: the Georgetown University experience. Front Oncol. 2016, 6:114. 10.3389\/fonc.2016.00114","journal-title":"Front Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.175","article-title":"Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations","volume":"14","author":"Tosoian JJ","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017, 14:15-25. 10.1038\/nrurol.2016.175","journal-title":"Nat Rev Urol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum RR","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011, 8:378-82. 10.1038\/nrclinonc.2011.44","journal-title":"Nat Rev Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.2539","article-title":"Multi-institutional analysis of prostate-specific antigen kinetics after stereotactic body radiation therapy","volume":"105","author":"Jiang NY","year":"2019","unstructured":"Jiang NY, Dang AT, Yuan Y, et al.. Multi-institutional analysis of prostate-specific antigen kinetics after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2019, 105:628-36. 10.1016\/j.ijrobp.2019.06.2539","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00382-9","article-title":"18F-Fluciclovine PET\/CT performance in biochemical recurrence of prostate cancer: a systematic review","volume":"24","author":"Rais-Bahrami S","year":"2021","unstructured":"Rais-Bahrami S, Efstathiou JA, Turnbull CM, et al.. 18F-Fluciclovine PET\/CT performance in biochemical recurrence of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2021, 24:997-1006. 10.1038\/s41391-021-00382-9","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.606260","article-title":"Rationale for involved field stereotactic body radiation therapy-enhanced intermittent androgen deprivation therapy in hormone-sensitive nodal oligo-recurrent prostate cancer following prostate stereotactic body radiation therapy","volume":"10","author":"Carrasquilla M","year":"2020","unstructured":"Carrasquilla M, Creswell ML, Pepin AN, et al.. Rationale for involved field stereotactic body radiation therapy-enhanced intermittent androgen deprivation therapy in hormone-sensitive nodal oligo-recurrent prostate cancer following prostate stereotactic body radiation therapy. Front Oncol. 2020, 10:606260. 10.3389\/fonc.2020.606260","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle LF","year":"2021","unstructured":"Valle LF, Lehrer EJ, Markovic D, et al.. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol. 2021, 80:280-92. 10.1016\/j.eururo.2020.11.010","journal-title":"Eur Urol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2016.11.005","article-title":"Imaging of prostate cancer using fluciclovine","volume":"12","author":"Savir-Baruch B","year":"2017","unstructured":"Savir-Baruch B, Zanoni L, Schuster DM. Imaging of prostate cancer using fluciclovine. PET Clin. 2017, 12:145-57. 10.1016\/j.cpet.2016.11.005","journal-title":"PET Clin"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.600690","article-title":"Comparison of manual and semi-automatic [(18)F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference","volume":"10","author":"Spohn SK","year":"2020","unstructured":"Spohn SK, Kramer M, Kiefer S, et al.. Comparison of manual and semi-automatic [(18)F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference. Front Oncol. 2020, 10:600690. 10.3389\/fonc.2020.600690","journal-title":"Front Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004590","article-title":"Impact of 18 F-fluciclovine PET\/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy","volume":"48","author":"Lawal IO","year":"2023","unstructured":"Lawal IO, Marcus C, Schuster DM, et al.. Impact of 18 F-fluciclovine PET\/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy. Clin Nucl Med. 2023, 48:e153-9. 10.1097\/RLU.0000000000004590","journal-title":"Clin Nucl Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"(18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani AB","year":"2021","unstructured":"Jani AB, Schreibmann E, Goyal S, et al.. (18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial. Lancet. 2021, 397:1895-904. 10.1016\/S0140-6736(21)00581-X","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020304","article-title":"18F-fluciclovine positron emission tomography in prostate cancer: a systematic review and diagnostic meta-analysis","volume":"11","author":"Biscontini G","year":"2021","unstructured":"Biscontini G, Romagnolo C, Cottignoli C, et al.. 18F-fluciclovine positron emission tomography in prostate cancer: a systematic review and diagnostic meta-analysis. Diagnostics (Basel). 2021, 11:10.3390\/diagnostics11020304","journal-title":"Diagnostics (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais J","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, et al.. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019, 20:1286-94. 10.1016\/S1470-2045(19)30415-2","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020191689","article-title":"PSMA-targeted radiotracers versus (18)F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis","volume":"296","author":"Tan N","year":"2020","unstructured":"Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, Davenport MS. PSMA-targeted radiotracers versus (18)F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020, 296:44-55. 10.1148\/radiol.2020191689","journal-title":"Radiology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313128-timing-and-patterns-of-potentially-salvageable-recurrences-following-stereotactic-body-radiosurgery-for-clinically-localized-prostate-cancer-assessed-by-preferential-amino-acid-uptake","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T14:30:06Z","timestamp":1737815406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313128-timing-and-patterns-of-potentially-salvageable-recurrences-following-stereotactic-body-radiosurgery-for-clinically-localized-prostate-cancer-assessed-by-preferential-amino-acid-uptake"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.77964","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}